(Q44677340)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

pancreatic adenocarcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Jean-Baptiste Bachet

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

L Marthey

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

J F Blanc

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

M Gauthier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

A Cueff

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

E Francois

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

I Trouilloud

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

D Malka

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

R Coriat

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

E Terrebonne

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

C De La Fouchardière

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

S Manfredi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

D Solub

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

C Lécaille

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

A Thirot Bidault

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

F Carbonnel

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

J Taieb

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

19 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

Annals of Surgical Oncology

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

295-301

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037971%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Patient and hospital characteristics on the variance of perioperative outcomes for pancreatic resection in the United States: a plea for outcome-based and not volume-based referral guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3898-9